Stable black phosphorus/Bi<sub>2</sub>O<sub>3</sub> heterostructures for synergistic cancer radiotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29677520.
- Also identified by DOI 10.1016/j.biomaterials.2018.04.022.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
X-ray induced photodynamic therapy (X-ray-PDT) is a promising approach for synergistic cancer radiotherapy and development of suitable radiosensitizers is highly desired. In this paper, we propose black phosphorus/Bi<sub>2</sub>O<sub>3</sub> (BP/Bi<sub>2</sub>O<sub>3</sub>) heterostructures as efficient and biocompatible radiosensitizers for synergistic cancer radiotherapy. The heterostructures are synthesized by growth of ultrasmall Bi<sub>2</sub>O<sub>3</sub> nanoparticles onto BP nanosheets. The Bi<sub>2</sub>O<sub>3</sub> decoration inhibits the rapid degradation of BP nanosheets by occupation of the defect sites, and the synergistic effects of BP and Bi<sub>2</sub>O<sub>3</sub> enable <sup>1</sup>O<sub>2</sub> overproduction under X-ray irradiation. This X-ray-PDT effect of the BP/Bi<sub>2</sub>O<sub>3</sub> nanosheets enhances the radiotherapy activity towards cancer cells by inducing cell apoptosis and cycle arrest. In vivo treatment of melanoma conducted on a clinical radiotherapeutic instrument demonstrates that the BP/Bi<sub>2</sub>O<sub>3</sub> sensitized radiotherapy inhibits tumor growth efficiently. Furthermore, the BP/Bi<sub>2</sub>O<sub>3</sub> nanosheets composed of biological friendly P, O, and Bi elements shows good biocompatibility in vitro and in vivo. This radiosensitizer thus has immense clinical potential for cancer therapy, and our findings reveal a general strategy to fabricate stable BP-based heterostructures for different applications.
Medical subject headings
- Bismuth
- Neoplasms
- Phosphorus